Helix BioPharma Announces Director Resignation
17 Dezember 2013 - 2:59PM
Marketwired
Helix BioPharma Announces Director Resignation
AURORA, ON--(Marketwired - Dec 17, 2013) - Helix BioPharma
Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company
developing drug candidates for the prevention and treatment of
cancer, today announced that Mario Gobbo has resigned from Helix's
board of directors.
Commenting on the resignation, Robert A. Verhagen, Helix's Chief
Executive Officer, said, "Mr. Gobbo became a director in March 2012
and subsequently assumed the role of Chair of the board in January
2013. He also served on each of the audit, compensation and
governance committees of the board during his tenure, including as
chair of the audit committee and, most recently, the governance
committee. Mr. Gobbo served on the board during a period of
transition as Helix made a number of key business and strategic
decisions to refocus itself and its operations. We thank Mr.
Gobbo for his service and wish him well in the future."
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company
specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix's
product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently
listed on the TSX and FSE under the symbol "HBP".
Investor Relations: Helix BioPharma Corp. Tel: 905 841-2300
Email: ir@helixbiopharma.com
Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Mai 2023 bis Mai 2024